Pharmaceutical

AdAlta and SYNthesis to form AdCella for advanced cancer treatments

AdAlta has signed an MOU with SYNthesis to explore the creation of a jointly owned special purpose entity, AdCella.

Apr 9, 2024 - 00:00
AdAlta and SYNthesis to form AdCella for advanced cancer treatments
AdAlta has signed an MOU with SYNthesis to explore the creation of a jointly owned special purpose entity, AdCella.
Read the original article

Tags:

Previous Article

Sensorion raises $16m for gene therapies to treat deafness

Next Article

Medicxi and Starpharma to develop dendrimer-based cancer treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

STAT+: Pharmalittle: White House takes aim at pharma pa...

Dec 7, 2023

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Eli Lilly reiterates POINT acquisition plans with tende...

Nov 12, 2023

Eli Lilly’s retatrutide sets new record for weight loss in obesity space

Eli Lilly’s retatrutide sets new record for weight loss...

Jul 3, 2023